New migraine pill could be offered to thousands of sufferers on the NHS - common symptoms and causes
The National Institute for Health and Care Excellence has today published draft guidance recommending the drug Rimegepant as an option for preventing migraines in up to 145,000 adults, if previous treatments have failed. The guidance recommends that the pill, made by Pfizer, should be given to adults who have at least four migraine attacks a month but fewer than 15.
Current headache treatments, which include beta-blockers, antidepressants and epilepsy medicine, can have significant side effects and can be ineffective, according to Nice. Final guidance on the use of the new drug, which is taken as a wafer which dissolves under the tongue, is expected next month if there are no appeals.
Toby Cousens, head of hospital and internal medicine at Pfizer UK, said: “On top of debilitating physical symptoms, migraine can place significant pressure on the professional and personal lives of those living with it, including being forced to take time off work. If you have problems with your sight, such as seeing zig zag lines or flashing lights, or dizziness and difficulty speaking, you may be experiencing migraine with aura. Aura symptoms should not last for longer than an hour.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
NHS backs new wafer to prevent migrainesRimegepant will be available only to adults who have tried at least three other preventative drugs.
Consulte Mais informação »
Spyware maker NSO has a new owner amid new hacking reportsPegasus-pusher NSO gets new owner keen on the commercial spyware biz
Consulte Mais informação »
Three New China-Russia-Iran and Iraq Agreements Confirm The New Oil Market Order | OilPrice.comThree most recent principal cooperation agreements between China, Russia and Iran will have immediate consequences for oil and gas flows around the world and their pricing
Consulte Mais informação »
Regulators to review hospital trust after claims of bullying and intimidationRegulators to review hospital trust after claims of bullying and intimidation from whistleblowers
Consulte Mais informação »
Data platforms for all under controversial NHS plansProcurement under threat of legal action imagines trusts will tailor systems for their own use cases
Consulte Mais informação »